Regulatory decisions affecting biopharma products in development, including: Acacia, Alnylam, Amgen, Ascletis, Biocryst, Biohaven, Biomarin, BMS, Can-Fite, Cortexyme, Debiopharm, Eli Lilly, Enochian, Epizyme, Fibrogen, Forma, Genentech, Genmab, GSK, Heron, Horizon, Incyte, Innocoll, Inovio, Ionis, Janssen, Jazz, Kiadis, Kyowa Kirin, Logicbio, Lysogene, Merck, Mesoblast, Monopar, Nanobiotix, Neurosense, Novan, Novartis, Pharmamar, Phasebio, Protalix, Puma, Revance, Roche, Shionogi, Sirnaomics, Soligenix, Takeda, Trevena, Ultragenyx, United, Y-mabs, Zai Lab, Zogenix.